Phytopharm PLC
14 April 2008
TR-1: notification of major interests in shares
1. Identity of the issuer or the Phytopharm plc
underlying issuer of existing shares to
which voting rights are attached:
2. Reason for the notification (please tick the appropriate box or
boxes)
An acquisition or disposal of voting rights YES
An acquisition or disposal of financial instruments which may result in
the acquisition of shares already issued to which voting rights are
attached
An event changing the breakdown of voting rights
Other (please specify): Placing
3. Full name of person(s) subject to the RAB Capital plc
notification obligation:
4. Full name of shareholder(s) (if Credit Suisse Client Nominees (UK) Limited
different from 3.):
5. Date of the transaction (and date on 29/02/08
which the threshold is crossed or reached
if different)
6. Date on which issuer notified: 11/04/08
7. Threshold(s) that is/are
crossed or reached: 3%
8. Notified details:
A: Voting rights attached to shares
Class/type Situation previous to the Resulting situation after the triggering
of shares Triggering transaction transaction
if possible
using the Number of Number of Voting Number Number of voting % of voting
ISIN CODE Shares Rights of rights rights
shares
Direct Direct Indirect xi Direct Indirect
x
Ordinary 1
Pence Nil Nil Nil Nil 3,400,326 Nil 3.60%
GB000686972
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting rights that may % of
financial date Conversion be acquired if the instrument is voting
instrument Period/ Date exercised/ converted. rights
Total (A+B)
Number of voting rights % of voting rights
3,400,326 3.60%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
RAB Capital plc ('PLC') acts as investment manager for RAB Special Situations
(Master) Fund Limited ('SS') and RAB Innovations (Master) Fund Limited
('Innovations') and makes filings on behalf of these entities under DTR 5.2.1.
PLC does not act as custodian for its clients and therefore the shares are held
in the nominee name of the custodian of its clients, which is Credit Suisse
Client Nominees (UK) Limited for SS and Goldman Sachs Securities (Nominees)
Limited for Innovations.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information: Notification using the total voting rights
figure of 94,544,038
14. Contact name: Zoe McGowan, Company Secretary
15. Contact telephone number: 01480 437697
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.